EA202091302A1 - Замещенные азабициклы в качестве положительных аллостерических модуляторов мускаринового рецептора m1 - Google Patents
Замещенные азабициклы в качестве положительных аллостерических модуляторов мускаринового рецептора m1Info
- Publication number
- EA202091302A1 EA202091302A1 EA202091302A EA202091302A EA202091302A1 EA 202091302 A1 EA202091302 A1 EA 202091302A1 EA 202091302 A EA202091302 A EA 202091302A EA 202091302 A EA202091302 A EA 202091302A EA 202091302 A1 EA202091302 A1 EA 202091302A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- positive allosteric
- allosteric modulators
- muscarine receptor
- azabicycles
- substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Настоящее изобретение относится к соединениям формулы (I) или их изотопным формам, стереоизомерам, таутомерам или их фармацевтически приемлемым солям в качестве положительных аллостерических модуляторов мускаринового рецептора M1 (PAM M1). Настоящее изобретение описывает способы получения, фармацевтическую композицию, комбинации и применение соединения формулы (I), его стереоизомеров, изотопных форм или фармацевтически приемлемых солей.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201741042082 | 2017-11-23 | ||
PCT/IB2018/059164 WO2019102365A1 (en) | 2017-11-23 | 2018-11-21 | Substituted azacycles as muscarinic m1 receptor positive allosteric modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
EA202091302A1 true EA202091302A1 (ru) | 2020-08-17 |
EA039902B1 EA039902B1 (ru) | 2022-03-25 |
Family
ID=64744766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202091302A EA039902B1 (ru) | 2017-11-23 | 2018-11-21 | Замещенные азабициклы в качестве положительных аллостерических модуляторов мускаринового рецептора m1 |
Country Status (19)
Country | Link |
---|---|
US (1) | US20210369685A1 (ru) |
EP (1) | EP3713940B1 (ru) |
JP (1) | JP7034284B2 (ru) |
KR (1) | KR102443402B1 (ru) |
CN (1) | CN111386270B (ru) |
AU (1) | AU2018372664B2 (ru) |
BR (1) | BR112020010138A2 (ru) |
CA (1) | CA3082724C (ru) |
DK (1) | DK3713940T3 (ru) |
EA (1) | EA039902B1 (ru) |
HR (1) | HRP20220736T1 (ru) |
HU (1) | HUE058954T2 (ru) |
IL (1) | IL274708B (ru) |
MA (1) | MA50806A (ru) |
MX (1) | MX2020005341A (ru) |
NZ (1) | NZ764561A (ru) |
SG (1) | SG11202004580WA (ru) |
WO (1) | WO2019102365A1 (ru) |
ZA (1) | ZA202002938B (ru) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2588104B1 (en) | 2010-07-01 | 2014-12-10 | Merck Sharp & Dohme Corp. | Isoindolone m1 receptor positive allosteric modulators |
US9206200B2 (en) | 2011-05-17 | 2015-12-08 | Merck Sharp & Dohme Corp. | N-linked lactam M1 receptor positive allosteric mogulators |
ES2604958T3 (es) | 2011-10-28 | 2017-03-10 | Vanderbilt University | Análogos de 2-(4-heterociclilbencil)isoindolin-1-ona sustituidos como moduladores alostéricos positivos del receptor muscarínico de acetilcolina M1 |
KR102349237B1 (ko) | 2014-04-23 | 2022-01-07 | 다케다 야쿠힌 고교 가부시키가이샤 | 알츠하이머 병의 치료를 위한 콜린작동성 무스카린 m1 수용체 양성 알로스테릭 조절인자 활성을 갖는 이소인돌린-1-온 유도체 |
ES2789756T3 (es) * | 2015-12-23 | 2020-10-26 | Merck Sharp & Dohme | Moduladores alostéricos de 6,7-dihidro-5H-pirrolo[3,4-b]piridin-5-ona del receptor de acetilcolina muscarínico M4 |
WO2018005249A1 (en) * | 2016-06-28 | 2018-01-04 | Merck Sharp & Dohme Corp. | Benzoisoquinolinone m1 receptor positive allosteric modulators |
-
2018
- 2018-11-21 DK DK18822142.8T patent/DK3713940T3/da active
- 2018-11-21 BR BR112020010138-9A patent/BR112020010138A2/pt unknown
- 2018-11-21 US US16/766,112 patent/US20210369685A1/en active Pending
- 2018-11-21 JP JP2020528300A patent/JP7034284B2/ja active Active
- 2018-11-21 EP EP18822142.8A patent/EP3713940B1/en active Active
- 2018-11-21 KR KR1020207017949A patent/KR102443402B1/ko active IP Right Grant
- 2018-11-21 NZ NZ764561A patent/NZ764561A/en unknown
- 2018-11-21 MA MA050806A patent/MA50806A/fr unknown
- 2018-11-21 CA CA3082724A patent/CA3082724C/en active Active
- 2018-11-21 EA EA202091302A patent/EA039902B1/ru unknown
- 2018-11-21 CN CN201880075861.2A patent/CN111386270B/zh active Active
- 2018-11-21 HU HUE18822142A patent/HUE058954T2/hu unknown
- 2018-11-21 SG SG11202004580WA patent/SG11202004580WA/en unknown
- 2018-11-21 HR HRP20220736TT patent/HRP20220736T1/hr unknown
- 2018-11-21 WO PCT/IB2018/059164 patent/WO2019102365A1/en unknown
- 2018-11-21 MX MX2020005341A patent/MX2020005341A/es unknown
- 2018-11-21 AU AU2018372664A patent/AU2018372664B2/en active Active
-
2020
- 2020-05-17 IL IL274708A patent/IL274708B/en unknown
- 2020-05-20 ZA ZA2020/02938A patent/ZA202002938B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA202002938B (en) | 2021-04-28 |
CN111386270A (zh) | 2020-07-07 |
KR102443402B1 (ko) | 2022-09-15 |
US20210369685A1 (en) | 2021-12-02 |
WO2019102365A1 (en) | 2019-05-31 |
CN111386270B (zh) | 2022-05-03 |
HUE058954T2 (hu) | 2022-10-28 |
CA3082724A1 (en) | 2019-05-31 |
DK3713940T3 (da) | 2022-06-20 |
BR112020010138A2 (pt) | 2020-11-10 |
NZ764561A (en) | 2021-12-24 |
SG11202004580WA (en) | 2020-06-29 |
HRP20220736T1 (hr) | 2022-09-02 |
EA039902B1 (ru) | 2022-03-25 |
CA3082724C (en) | 2022-05-31 |
JP2021504357A (ja) | 2021-02-15 |
IL274708A (en) | 2020-07-30 |
AU2018372664A1 (en) | 2020-06-04 |
IL274708B (en) | 2022-06-01 |
EP3713940B1 (en) | 2022-05-04 |
EP3713940A1 (en) | 2020-09-30 |
JP7034284B2 (ja) | 2022-03-11 |
AU2018372664B2 (en) | 2020-11-19 |
MA50806A (fr) | 2020-09-30 |
KR20200090854A (ko) | 2020-07-29 |
MX2020005341A (es) | 2020-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019002180A (es) | Moduladores alostericos positivos del receptor m1 muscarinico. | |
EA202090486A2 (ru) | Соединения для лечения спинальной мышечной атрофии | |
EA201891103A1 (ru) | Композиции для лечения спинальной мышечной атрофии | |
PH12016501440A1 (en) | Novel heterocyclic compounds | |
EA201791256A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
EA201891179A1 (ru) | N-замещенные индольные производные в качестве модуляторов pge2 рецепторов | |
MX2021002382A (es) | Sales y formas cristalinas de modulador alosterico positivo gabaa. | |
EA201990388A1 (ru) | Пиперидиновые модуляторы рецепторов cxcr7 | |
EA201692542A1 (ru) | Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы | |
EA201992679A1 (ru) | N-замещенные индольные производные | |
EA202091256A1 (ru) | Новые антагонисты рецептора брадикинина | |
EA201690888A1 (ru) | Новые гетероциклические соединения | |
EA201792374A1 (ru) | Азабензимидазолы и их применение в качестве модуляторов рецептора ampa | |
EA201792594A1 (ru) | Положительные аллостерические модуляторы мусаринового рецептора м1 | |
EA201791600A1 (ru) | Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора | |
EA201890534A1 (ru) | Новые аннелированные феноксиацетамиды | |
EA201590364A1 (ru) | Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда | |
EA202092829A1 (ru) | Композиции тофацитиниба с контролируемым высвобождением | |
EA201890684A1 (ru) | Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1 | |
EA201501163A1 (ru) | Модуляторы рецептора cxcr7 | |
EA202090995A1 (ru) | Полициклические амиды в качестве положительных аллостерических модуляторов мускариновых рецепторов м1 | |
EA202090925A1 (ru) | Гетероарильные соединения в качестве позитивных аллостерических модуляторов мускаринового рецептора m1 | |
EA201991045A1 (ru) | Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора | |
EA202191046A1 (ru) | Производные пирролопиридазина, как позитивные аллостерические модуляторы мускаринового рецептора m1 | |
EA202091302A1 (ru) | Замещенные азабициклы в качестве положительных аллостерических модуляторов мускаринового рецептора m1 |